345 related articles for article (PubMed ID: 29807823)
21. Overactive Bladder.
White N; Iglesia CB
Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
[TBL] [Abstract][Full Text] [Related]
22. The evaluation and management of refractory neurogenic overactive bladder.
Kurpad R; Kennelly MJ
Curr Urol Rep; 2014 Oct; 15(10):444. PubMed ID: 25118853
[TBL] [Abstract][Full Text] [Related]
23. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of novel therapies for overactive bladder.
Mayr CA; Shepherd JP
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
[TBL] [Abstract][Full Text] [Related]
25. [Standard pharmacological treatment and new therapies for overactive bladder].
Del Popolo G; Mencarini M; Li Marzi V
Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
[TBL] [Abstract][Full Text] [Related]
26. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
Zahner PM; Giusto LL; Goldman HB
Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
[TBL] [Abstract][Full Text] [Related]
27. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Leong RK; De Wachter SG; van Kerrebroeck PE
Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
[TBL] [Abstract][Full Text] [Related]
28. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy.
Bhide AA; Tailor V; Fernando R; Khullar V; Digesu GA
Int Urogynecol J; 2020 May; 31(5):865-870. PubMed ID: 31853597
[TBL] [Abstract][Full Text] [Related]
29. Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder.
Beusterien K; Kennelly MJ; Bridges JF; Amos K; Williams MJ; Vasavada S
Neurourol Urodyn; 2016 Nov; 35(8):1028-1033. PubMed ID: 26370222
[TBL] [Abstract][Full Text] [Related]
30. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
[TBL] [Abstract][Full Text] [Related]
31. [Treatment for refractory non-neurogenic overactive bladder].
Gamé X; Phé V
Prog Urol; 2020 Nov; 30(14):920-930. PubMed ID: 33220820
[TBL] [Abstract][Full Text] [Related]
32. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
33. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder.
Juszczak K; Adamczyk P; Maciukiewicz P; Drewa T
Pharmacol Rep; 2018 Dec; 70(6):1133-1138. PubMed ID: 30317128
[TBL] [Abstract][Full Text] [Related]
35. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity.
Joussain C; Phé V; Even A; Chartier-Kastler E; Denys P
Eur J Phys Rehabil Med; 2017 Dec; 53(6):991-997. PubMed ID: 29072045
[TBL] [Abstract][Full Text] [Related]
36. Management of refractory OAB in the non-neurogenic patient.
Wadie BS
Curr Urol Rep; 2014 Sep; 15(9):438. PubMed ID: 25015301
[TBL] [Abstract][Full Text] [Related]
37. [Botulinum toxin A for idiopathic overactive bladder in women].
Hampel C
Urologie; 2024 Jul; 63(7):658-665. PubMed ID: 38922399
[TBL] [Abstract][Full Text] [Related]
38. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States.
Jiang J; Patil D; Traore EJ; Hammett J; Filson CP
Urology; 2020 Aug; 142():87-93. PubMed ID: 32437771
[TBL] [Abstract][Full Text] [Related]
39. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy.
Ridout AE; Yoong W
J Obstet Gynaecol; 2010 Feb; 30(2):111-4. PubMed ID: 20143965
[TBL] [Abstract][Full Text] [Related]
40. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
